ASLAN Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares
01 Mars 2021 - 10:01PM
ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage immunology
focused biopharmaceutical company developing innovative treatments
to transform the lives of patients, today announced that it has
commenced an underwritten public offering of $60.0 million of its
American Depositary Shares (“ADSs”) representing ordinary shares.
In addition, ASLAN expects to grant the underwriters a 30-day
option to purchase up to an additional $9.0 million of ADSs in the
public offering on the same terms and conditions. All ADSs to be
sold in the offering will be offered by ASLAN. The offering is
subject to market conditions, and there can be no assurance as to
whether or when the offering may be completed or as to the actual
size or terms of the offering.
ASLAN expects to use the net proceeds from the offering,
together with its existing cash and cash equivalents, primarily to
fund its planned ASLAN004 Phase 2b dose-range finding trial in
moderate-to-severe atopic dermatitis patients. ASLAN is also
required to repay $2.25 million of principal amount plus accrued
and unpaid interest under its loan facilities entered into in
October and November 2019 with the net proceeds from this offering.
The remainder of the net proceeds, if any, will be used to fund new
and other ongoing research and development activities, working
capital and other general corporate purposes.
Jefferies LLC and Piper Sandler & Co. are acting as joint
book-running managers for the offering.
The securities described above are being offered by ASLAN
pursuant to a shelf registration statement on Form F-3, including a
base prospectus, that was previously filed by ASLAN with
the Securities and Exchange Commission (the “SEC”) and
that was declared effective on February 11, 2021. A preliminary
prospectus supplement and accompanying prospectus relating to the
offering will be filed with the SEC and will be available
for free on the SEC’s website located at http://www.sec.gov.
Before you invest, you should read the preliminary prospectus
supplement and accompanying prospectus and other documents we have
filed with the SEC for more complete information about us and this
offering. An electronic copy of the preliminary prospectus
supplement and the accompanying prospectus relating to the
offering, when available, may be obtained by contacting Jefferies
LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison
Avenue, 2nd Floor, New York, NY 10022, by e-mail at
prospectus_department@jefferies.com or by telephone at (877)
821-7388; or Piper Sandler & Co., Attention: Prospectus
Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by
telephone at 800-747-3924 or by email at prospectus@psc.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals (Nasdaq:ASLN) is a clinical-stage
immunology focused biopharmaceutical company developing innovative
treatments to transform the lives of patients. Led by a senior
management team with extensive experience in global development and
commercialisation, ASLAN has a clinical portfolio comprised of a
potential first-in-class monoclonal therapy, ASLAN004, that is
being developed in atopic dermatitis and other immunology
indications, and ASLAN003, that it plans to develop for autoimmune
disease.
Forward Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The press release may, in some
cases, use terms such as “predicts,” “believes,” “potential,”
“proposed,” “continue,” “estimates,” “anticipates,” “expects,”
“plans,” “intends,” “may,” “could,” “might,” “will,” “should” or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. Forward-looking
statements include statements regarding the size, completion and
timing of the proposed public offering and the anticipated use of
proceeds therefrom. Actual results or developments may differ
materially from those projected or implied in these forward-looking
statements. Factors that may cause such a difference include risks
and uncertainties related to completion of the proposed public
offering on the anticipated terms or at all, market conditions and
the satisfaction of customary closing conditions related to the
proposed public offering. More information about the risks and
uncertainties faced by ASLAN is contained in the section captioned
“Risk Factors” in Exhibit 99.1 to ASLAN’s Report on Form 6-K filed
with the SEC on March 1, 2021. Any forward-looking statements that
are made in this press release speak only as of the date of this
press release. ASLAN assumes no obligation to update the
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
Media contact
Emma ThompsonSpurwing CommunicationsTel: +65 6571
2021Email: ASLAN@spurwingcomms.com |
Robert UhlWestwicke PartnersTel: +1 858 356 5932
Email: robert.uhl@westwicke.com |
ASLAN Pharmaceuticals (NASDAQ:ASLN)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
ASLAN Pharmaceuticals (NASDAQ:ASLN)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024